PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-63.84%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-88.24%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-87.91%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-87.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative OCF growth while AGEN is at 28.22%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-63.84%
Negative FCF growth while AGEN is at 28.46%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
Positive long-term OCF/share growth while AGEN is negative. John Neff would see a structural advantage in sustained cash generation.
53.61%
5Y OCF/share CAGR at 50-75% of AGEN's 73.72%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
53.61%
3Y OCF/share CAGR at 75-90% of AGEN's 63.37%. Bill Ackman would press for improvements in margin or overhead to catch up.
35.25%
Positive 10Y CAGR while AGEN is negative. John Neff might see a substantial advantage in bottom-line trajectory.
35.25%
5Y net income/share CAGR at 75-90% of AGEN's 43.32%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
35.25%
3Y net income/share CAGR 75-90% of AGEN's 42.96%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Positive asset growth while AGEN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-28.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
50.95%
Debt growth of 50.95% while AGEN is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth well above AGEN's 4.17%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.